Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À§¼±¾Ï¼¼Æ÷¿¡¼­ ¼¼Æ÷³» Cyclic AMPÀÇ Áõ°¡°¡ Epidermal Growth Factor ¼ö¿ëü°æÇÕ¿¡ ¹ÌÄ¡´Â ¿µÇâ Effect of Intracellular Cyclic AMP an EGF Receptor Binding in Human Gastric Adenocarcinoma Cells

´ëÇѾÏÇÐȸÁö 1993³â 25±Ç 2È£ p.166 ~ 169
±è¼±È¸, Á¤ÇØÀÏ,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¼±È¸ (  ) 
¼­¿ï´ëÇб³ Ä¡°ú´ëÇÐ ±³Á¤Çб³½Ç

Á¤ÇØÀÏ (  ) 
¼­¿ï´ëÇб³

Abstract


Different types of cyclic AMP(cAMP) analogues and the agents increasing intracellular cAMP have growth inhibitory effect on epithelial origin cancer cell lines including gastric cancer. Transforming growth factor ¥á(TGF¥á) is a possible autocrine
growth
factor of normal and neoplastic epithelial cells, since it has been shown that TGF¥á and its receptor(FGF receptor: EGFr) are expressed in those cells, growth of which are stimulated by TGFa. The purpose of our study is to find whither increasing
intracellular cAMP has any effect on EGFr binding. AGS human gastric cancer cell line was used because AGS cells express TGF¥á and its receptor and TGF¥á/EGF stimulates and cAMP inhibits the growth of AGS. Vasoactive intestinal
polypeptide(VIP)910E-7M)
plus isobutylmethylxanthine(IBMX; 10E-3M) stimulated cAMP production in AGS cells has a high-affinity single type EGFr and 24 hour treatment of these agents decreased the binding capacity(Bmax: control vs treated; 7.27 fmole/10E6 cells vs 5.41
fmole/10E6 cells) and increased affinity(Kd: control vs treated;80.8fM vs 39.6fM), which is representative data from triple experiments. In conclusion, increased intracellular cAMP affects EGFr binding on the AGS cell membrane and we need to
investigate
further whether this phenomenon is related to the effect on cell growth.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS